5-氰基-1-甲基-1H-吡咯-2-硼酸 | 860617-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 5-氰基-1-甲基-1H-吡咯-2-硼酸
• 英文名称: (5-cyano-1-methyl-1H-pyrrol-2-yl)boronic acid
• 英文别名: 5-Cyano-1-methyl-1H-pyrrol-2-ylboronic acid；(5-cyano-1-methylpyrrol-2-yl)boronic acid
• CAS: 860617-71-6
• 化学式: C₆H₇BN₂O₂
• mdl: MFCD11976642
• 分子量: 149.945
• InChiKey: CMPMUHFINOXALE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.42
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  3

SDS

5-氰基-1-甲基-1H-吡咯-2-硼酸MSDS英文版

反应信息

• 作为反应物：
  描述：

  5-氰基-1-甲基-1H-吡咯-2-硼酸 在 吡啶 、 potassium fluoride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 作用下， 以 四氢呋喃 为溶剂， 生成 N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-3-(trifluoromethyl)phenyl]ethane-sulfonamide
  参考文献：
  名称：

  Novel progesterone receptor modulators: 4-Aryl-phenylsulfonamides

  摘要：

  We have developed a new series of progesterone receptor modulators based upon the 4-aryl-phenylsulfonamide. Initial work in the series afforded potent compounds with good properties, however an advanced intermediate proved to be genotoxic in a non-GLP Ames assay following metabolic activation. We subsequently solved this problem and identified advanced leads which demonstrated oral efficacy in rhesus monkey pharmacodynamic and kinetics models. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.077
• 作为产物：
  描述：

  二异丙基(5-氰基-1-甲基-1H-吡咯-2-基)硼酸酯 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 乙酸乙酯 、 水 为溶剂， 以59%的产率得到5-氰基-1-甲基-1H-吡咯-2-硼酸
  参考文献：
  名称：

  Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof

  摘要：

  公式I的孕酮受体调节剂，或其药用盐， 其中R1，R2，R3，R4，R5，R6和R7如本文所定义。这些化合物对避孕和激素替代疗法有用。还提供含有这些化合物的产品。

  公开号：

  US20070027125A1

文献信息

• [EN] DIHYDROOXADIAZINONES<br/>[FR] DIHYDROOXADIAZINONES
  申请人：BAYER AG

  公开号：WO2019025562A1

  公开（公告）日：2019-02-07

  The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

  本发明提供了一般式(I)的二氢氧二氮酮化合物：其中R1、R2、R3和R4如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖性疾病，作为唯一药剂或与其他活性成分组合使用。
• ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR
  申请人：McComas Casey Cameron

  公开号：US20080221201A1

  公开（公告）日：2008-09-11

  In one embodiment, compounds of the following structure are described, wherein R 1 to R 7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; treating or preventing uterine leiomyomata; treating or preventing endometriosis, dysfunctional bleeding, and polycystic ovary syndrome; treating or preventing hormone-dependent carcinomas; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; and treating cycle-related symptoms using the compounds described herein.

  在一个实施例中，描述了以下结构的化合物，其中R1到R7在此处描述。 还提供了制备这些化合物的方法以及避孕的方法；治疗或预防纤维瘤；治疗或预防子宫平滑肌瘤；治疗或预防子宫内膜异位症、功能性出血和多囊卵巢综合征；治疗或预防激素依赖性癌症；提供激素替代疗法；刺激食欲；同步发情；并使用此处描述的化合物治疗与周期相关的症状。
• Use of progesterone receptor modulators
  申请人：McComas Cameron Casey

  公开号：US20070027201A1

  公开（公告）日：2007-02-01

  The use of compounds of formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 , are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, treating uterine myometrial fibroids, treating endometriosis, treating benign prostatic hypertrophy, treating carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, and meningioma, inducing amenorrhea, cycle-related symptoms, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder are described. Also provided are products containing these compounds.

  使用I式化合物，或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6和R7如本文所定义，用于避孕、激素替代疗法、同步发情、治疗痛经、治疗功能性子宫出血、治疗子宫肌瘤、治疗子宫内膜异位症、治疗良性前列腺增生、治疗子宫内膜、卵巢、乳腺、结肠、前列腺、垂体和脑膜瘤的癌症和腺癌，诱导闭经、与周期相关症状，或治疗经前期综合征和经前期失调症状的描述。还提供了含有这些化合物的产品。
• Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
  申请人：McComas Cameron Casey

  公开号：US20070027126A1

  公开（公告）日：2007-02-01

  Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein, are useful for contraception and hormone replacement therapy are described. Also provided are products containing these compounds.

  公式I的孕酮受体调节剂，或其药用盐，其中R1、R2、R3、R4、R5、R6和R7如本文所定义，可用于避孕和激素替代疗法。还提供了含有这些化合物的产品。
• Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1<i>H</i>-indol-5-yl)-1-methyl-1<i>H</i>-pyrrole-2-carbonitrile (WAY-255348)
  作者：Andrew Fensome、William R. Adams、Andrea L. Adams、Tom J. Berrodin、Jeff Cohen、Christine Huselton、Arthur Illenberger、Jeffrey C. Kern、Valerie A. Hudak、Michael A. Marella、Edward G. Melenski、Casey C. McComas、Cheryl A. Mugford、Ov D. Slayden、Matthew Yudt、Zhiming Zhang、Puwen Zhang、Yuan Zhu、Richard C. Winneker、Jay E. Wrobel

  DOI：10.1021/jm701080t

  日期：2008.3.1

  We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et

  我们继续探索3,3-二烷基-5-芳基吲哚系列孕酮受体（PR）调节剂，以寻找用于女性保健的新药物：避孕，肌瘤，子宫内膜异位症和某些乳腺癌。先前，我们报道了该模板和相关模板的微妙结构变化在激动剂和拮抗剂特性之间产生了功能转换（Fensome等，Biorg。Med。Chem。Lett。2002，12，3487; 2003，13，1317）。我们在本文中报道了5-（2-氧代吲哚-5-基）-1 H-吡咯-2-腈类化合物中的新功能开关。我们发现3，3-二烷基取代基的大小对于控制功能响应很重要。因此，小的基团（二甲基）提供有效的PR拮抗剂，而较大的基团（螺环己基）是PR激动剂。